TY - JOUR
T1 - Mitomycin C (MCC) in advanced soft tissue sarcoma
T2 - a phase II study of the EORTC soft tissue and Bone Sarcoma Group
AU - van Oosterom, A. T.
AU - Santoro, A.
AU - Bramwell, V.
AU - Davy, M.
AU - Mouridsen, H. T.
AU - Thomas, D.
AU - Sylvester, R.
PY - 1985
Y1 - 1985
N2 - Mitomycin C at a dose of 12 mg/m2 i.v. q 3 weeks was administered to 34 patients with measurable progressive advanced soft tissue sarcomas. No objective response was observed although in one of the 12 patients with overall stabilisation of disease a partial response was reported in lung lesions. The side-effects observed in this group of patients were generally mild. On the basis of this results the application of mitomycin C in this disease cannot be recommended.
AB - Mitomycin C at a dose of 12 mg/m2 i.v. q 3 weeks was administered to 34 patients with measurable progressive advanced soft tissue sarcomas. No objective response was observed although in one of the 12 patients with overall stabilisation of disease a partial response was reported in lung lesions. The side-effects observed in this group of patients were generally mild. On the basis of this results the application of mitomycin C in this disease cannot be recommended.
UR - http://www.scopus.com/inward/record.url?scp=0021813946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021813946&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(85)90037-9
DO - 10.1016/0277-5379(85)90037-9
M3 - Article
C2 - 3924625
AN - SCOPUS:0021813946
VL - 21
SP - 459
EP - 461
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -